Stocks › SNY
Sanofi (SNY) stock analysis
WEAK BUY 15% confidence · analysed Nov 4, 2026
On Nov 4, 2026, our model rated Sanofi (SNY) WEAK BUY with 15% confidence at a price of $45.33. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 79, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.3x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $46.11 and the swing low is $40.89; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 32.28, which looks expensive relative to its growth.
The company reports a profit margin of 8.2% and revenue growth of +15.7%.
In its latest quarter it earned $1.98 per share, which beat the $1.51 analysts expected, with revenue +15.7% year over year.
Wall Street's average rating is 2.1 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $53.48.
The next earnings report is expected around Jan 28, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $45.33, a target of $46.55 (+2.7%) and a stop-loss at $43.38 (-4.3%).
That is a reward-to-risk ratio of about 0.6 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 14, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.15 (WEAK BUY). Technicals: RSI 78.78, MACD bullish, price above SMA50. Fundamentals: PEG 32.28, margin 8.2%, revenue growth 15.7%. Financial results: YoY revenue +15.7%, last EPS surprise +31.1%, next earnings 2027-01-28. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block, equal highs above (resting liquidity). FinGPT news read: positive. Suggested levels: entry $45.33, target $46.55, stop-loss $43.38, exit by 2026-11-14 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for SNY
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 4, 2026 | WEAK BUY | 15% | $45.33 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on SNY
- Nov 3, 2026: NRIX Slumps 35% After-Hours Whats Driving The Selloff? (Stocktwits)
- Nov 3, 2026: Nurix Therapeutics stock tumbles on Sanofi program termination (Investing.com)
Frequently asked questions
Is SNY a buy right now?
As of Nov 4, 2026, our automated model rates Sanofi (SNY) WEAK BUY with 15% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for SNY?
The model's most recent plan targets $46.55 with a stop-loss at $43.38, from an entry near $45.33.
When does Sanofi report earnings next?
The next earnings report is expected around Jan 28, 2027.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.